Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Merck, ARIAD Announce SUCCEED Trial Results

By Drug Discovery Trends Editor | June 7, 2011

Merck and Ariad Pharmaceuticals, Inc. announced results from the Phase III Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus (SUCCEED) clinical trial, which evaluated oral ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy.

In this patient population, ridaforolimus improved progression-free survival (PFS), the primary endpoint of the study with a statistically significant 28% reduction in the risk of progression or death observed in those treated with ridaforolimus compared to placebo).The trial was a randomized, placebo-controlled, double-blind study of oral ridaforolimus administered at 40 mg/day, five days a week.  Oral ridaforolimus was granted a Special Protocol Assessment (SPA) by the FDA for the trial.

The most common side effects observed in the study were consistent with the known safety profile of ridaforolimus. The most common adverse events occurring at an incidence in the ridaforolimus group compared to placebo were stomatitis infections, fatigue, thrombocytopenia diarrhea, and cough. There were six deaths due to pulmonary disorders in the ridaforolimus treatment group and no deaths due to pulmonary disorders in the placebo group.

“Patients with metastatic soft-tissue and bone sarcomas have limited treatment options available to them. Data from the SUCCEED trial show that ridaforolimus maintained the benefit of prior conventional chemotherapy,” says Sant P. Chawla, MD, director, Sarcoma Oncology Center. “The study met the primary endpoint of progression-free survival, showing a clinically meaningful and statistically significant improvement in PFS in those patients treated with oral ridaforolimus.”

Based on these results, Merck plans to submit a New Drug Application (NDA) for ridaforolimus to the FDA and a marketing application in the European Union this year.

Release Date: June 6, 2011
Source: Ariad Pharmaceuticals, Inc. 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50